Page 21 - Read Online
P. 21

Page 12 of 13                Carciotto et al. Vessel Plus 2024;8:33  https://dx.doi.org/10.20517/2574-1209.2024.01

               Ethical approval and consent to participate
               Not applicable.


               Consent for publication
               Not applicable.


               Copyright
               © The Author(s) 2024.


               REFERENCES
               1.       Capodanno D, Alfonso F, Levine GN, Valgimigli M, Angiolillo DJ. ACC/AHA versus ESC guidelines on dual antiplatelet therapy. J
                   Am Coll Cardiol 2018;72:2915-31.  DOI  PubMed
               2.       Cao D, Chandiramani R, Chiarito M, Claessen BE, Mehran R. Evolution of antithrombotic therapy in patients undergoing
                   percutaneous coronary intervention: a 40-year journey. Eur Heart J 2021;42:339-51.  DOI  PubMed
               3.       Costa F, Windecker S, Valgimigli M. Dual antiplatelet therapy duration: reconciling the inconsistencies. Drugs 2017;77:1733-54.  DOI
                   PubMed
               4.       Giustino G, Costa F. Characterization of the individual patient risk after percutaneous coronary intervention. JACC Cardiovasc Interv
                   2019;12:831-4.  DOI  PubMed
               5.       Patrono C, Morais J, Baigent C, et al. Antiplatelet agents for the treatment and prevention of coronary atherothrombosis. J Am Coll
                   Cardiol 2017;70:1760-76.  DOI  PubMed
               6.       Cavender MA, Bhatt DL, et al. Consistent reduction in periprocedural myocardial infarction with cangrelor as assessed by multiple
                   definitions: findings from CHAMPION PHOENIX (cangrelor versus standard therapy to achieve optimal management of platelet
                   inhibition). Circulation 2016;134:723-33.  DOI  PubMed  PMC
               7.       Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med
                   2013;368:1303-13.  DOI  PubMed
               8.       Angiolillo DA, Galli M, Collet JP, Kastrati A, O’Donoghue MO. Antiplatelet therapy after percutaneous coronary intervention.
                   EuroIntervention 2022;17:e1371-96.  DOI  PubMed  PMC
               9.       Collet JP, Roffi M, Byrne RA, et al. Case-based implementation of the 2017 ESC focused update on dual antiplatelet therapy in
                   coronary artery disease. Eur Heart J 2018;39:e1-33.  DOI
               10.      Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J
                   2024;13:55-161.  DOI
               11.      Valgimigli M, Costa F, Lokhnygina Y, et al. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary
                   syndrome: lessons from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRACER)
                   randomized trial. Eur Heart J 2017;38:804-10.  DOI  PubMed  PMC
               12.      Capodanno D, Mehran R, Krucoff MW, et al. Defining strategies of modulation of antiplatelet therapy in patients with coronary artery
                   disease: a consensus document from the academic research consortium. Circulation 2023;147:1933-44.  DOI
               13.      Galli M, Laborante R, Andreotti F, et al. Bleeding complications in patients undergoing percutaneous coronary intervention. Rev
                   Cardiovasc Med 2022;23:286.  DOI  PubMed  PMC
               14.      Patrono C. Low-dose aspirin for the prevention of atherosclerotic cardiovascular disease. Eur Heart J 2024;45:2362-76.  DOI  PubMed
                   PMC
               15.      Sibbing D, Aradi D, Alexopoulos D, et al. Updated expert consensus statement on platelet function and genetic testing for guiding
                   P2Y12 receptor inhibitor treatment in percutaneous coronary intervention. JACC Cardiovasc Interv 2019;12:1521-37.  DOI  PubMed
               16.      Hwang D, Lim YH, Park KW, et al. Prasugrel dose de-escalation therapy after complex percutaneous coronary intervention in patients
                   with acute coronary syndrome: a post hoc analysis from the HOST-REDUCE-POLYTECH-ACS trial. JAMA Cardiol 2022;7:418.
                   DOI  PubMed  PMC
               17.      Galli M, Angiolillo DJ. De-escalation of antiplatelet therapy in acute coronary syndromes: why, how and when? Front Cardiovasc
                   Med 2022;9:975969.  DOI  PubMed  PMC
               18.      Cuisset T, Deharo P, Quilici J, et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing
                   of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J 2017;38:3070-8.  DOI  PubMed
               19.      Kim HS, Kang J, Hwang D, et al. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in
                   patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised
                   trial. The Lancet 2020;396:1079-89.  DOI
               20.      Kim CJ, Park MW, Kim MC, et al. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial
                   infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-
                   inferiority, randomised trial. The Lancet 2021;398:1305-16.  DOI
               21.      Tavenier AH, Mehran R, Chiarito M, et al. Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with
                   acute coronary syndrome: a meta-analysis. Eur Heart J 2022;8:492-502.  DOI
   16   17   18   19   20   21   22   23   24   25   26